NCT07684599
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07684599
Title A Study to Investigate Mocertatug Rezetecan as Maintenance Treatment for Participants With MMRp Endometrial Cancer (BEHOLD-Endometrial02)
Acronym BEHOLD-Endometrial02
Recruitment Recruiting
Gender female
Phase Phase III
Variant Requirements Yes
Sponsors GlaxoSmithKline
Indications
Therapies
Age Groups: senior | adult
Covered Countries CAN

Facility Status City State Zip Country Details
GSK Investigational Site RECRUITING Toronto Ontario M5G 1X6 Canada Details
GSK Investigational Site RECRUITING Montreal Quebec H4A 0B1 Canada Details
GSK Investigational Site RECRUITING Fukuoka 812-8582 Japan Details
GSK Investigational Site RECRUITING Fukushima 960-1295 Japan Details
GSK Investigational Site RECRUITING Hokkaido 060-8648 Japan Details
GSK Investigational Site RECRUITING Ibaraki 305-8576 Japan Details
GSK Investigational Site RECRUITING Miyagi 980-8574 Japan Details
GSK Investigational Site RECRUITING Numakunai 028-3695 Japan Details
GSK Investigational Site RECRUITING Osaka 569-8686 Japan Details
GSK Investigational Site RECRUITING Saitama 350-1298 Japan Details
GSK Investigational Site RECRUITING Tokyo 135-8550 Japan Details
GSK Investigational Site RECRUITING Daegu 700-712 South Korea Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field